Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 7, 2005; 11(45): 7197-7202
Published online Dec 7, 2005. doi: 10.3748/wjg.v11.i45.7197
Published online Dec 7, 2005. doi: 10.3748/wjg.v11.i45.7197
Parameter | Carnitine group, n = 75 | Placebo group, n = 75 |
Male/female | 50/25 | 45/30 |
Age (yr) | 51.7 ± 9.6 | 53.2 ± 9.2 |
Cirrhosis etiology | ||
Alcohol | 5 | |
Post-hepatitis B | 20 | 22 |
Post-hepatitis C | 38 | 38 |
Cryptogenetic | 10 | 10 |
Child–Pugh class | ||
A | 30 | 31 |
B | 34 | 34 |
C | 11 | 10 |
Prothrombin time (%) | 62.8 ± 6.9 | 63.1 ± 6.8 |
Serum albumin level (g/dL) | 2.9 ± 0.7 | 2.8 ± 0.9 |
Serum bilirubin level (mg/dL) | 3.1 ± 1.2 | 3.2 ± 1.4 |
Serum alanine | 119 ± 74 | 116 ± 77 |
aminotransferase level (IU/L) | ||
Blood urea nitrogen (mg/dL) | 40 ± 9 | 39 ± 11 |
Serum creatinine level (mg/dL) | 0.88 ± 0.21 | 0.82 ± 0.30 |
Natriemia (mEq/L) | 136 ± 3.4 | 138 ± 4.7 |
Kaliemia (mEq/L) | 4.1 ± 1.2 | 4.2 ± 0.9 |
Carnitine group (A) | Placebo group (B) | ||||||||
Duration of treatment (days) | 0 | 30 | 60 | 90 | 0 | 30 | 60 | 90 | |
NH4 fasting | MHE | 68.2±38.2 | 55.1±31.4 | 49.1±30.1 | 40.1±25.1 | 69.1±39.2 | 68.2±38.2 | 68.2±33.6 | 67.1±34.1 |
HE1 | 82.1±29.1 | 69.2±28.2 | 58.2±28.7 | 41.4±28.1 | 80.1±30.1 | 78.7±36.2 | 77.2±33.4 | 76.2±31.8 | |
HE2 | 89.2±34.2 | 80.1±28.1 | 74.1±12.9 | 53.2±18.2 | 88.2±34.1 | 87.1±35.2 | 86.1±38.1 | 85.4±39.2 | |
Trail making test-A | MHE | 48.9±18.7 | 35.1±18.9 | 30.9±15.2 | 274±12.4 | 51.4±19.2 | 50.2±18.9 | 52.1±20.1 | 50.4±20.2 |
HE1 | 62.4±21.2 | 50.8±18.9 | 40.8±16.5 | 33.6±16.1 | 60.9±19.9 | 59.9±19.8 | 58.4±20.1 | 53.6±19.8 | |
HE2 | 69.3±21.8 | 58.8±18.1 | 43.1±20.1 | 39.1±16.8 | 64.3±22.4 | 65.6±20.4 | 64.9±21.9 | 61.4±22.9 | |
Trail making test-B | MHE | 66.1±12.1 | 41.1±13.2 | 40.1±10.2 | 37.2±12.1 | 65.2±13.1 | 61.1±14.1 | 60.1±13.2 | 59±14.1 |
HE1 | 74.2±10.1 | 65±11.1 | 55.1±12.1 | 50.4±10.1 | 75.8±11.9 | 74.2±12.1 | 70.11±12.8 | 71.4±13.2 | |
HE2 | 96.9±12.4 | 87.4±11.2 | 75.11±11.8 | 61.9±13.2 | 91.4±12.1 | 90.6±10.8 | 91.5±10.6 | 93.4±11.8 | |
Symbol digit modalities test | MHE | 36±1.2 | 40±1.8 | 44±1.5 | 44±1.7 | 35±1.9 | 36±2.1 | 36.2±11.8 | 36.4±22.2 |
HE1 | 30±1.9 | 35.1±2.1 | 38±2.4 | 44±1.9 | 31.2±1.8 | 32.4±1.9 | 33.2±1.8 | 34.1±1.9 | |
HE2 | 25.1±1.4 | 28.2±1.9 | 32.1±12.4 | 38±2.4 | 26.1±2.1 | 27.2±2.4 | 28.1±1.9 | 27.9±1.8 | |
Block design test | MHE | 31.1±1.2 | 35.2±1.9 | 39±2.1 | 44±1.1 | 30.1±2.8 | 32±2.6 | 32.4±2.9 | 32.7±1.8 |
HE1 | 27±1.8 | 30±1.9 | 33.1±2.1 | 39.1±1.1 | 26±2.9 | 28±1.9 | 28.4±2.1 | 27.1±2.2 | |
HE2 | 22±1.9 | 26.1±1.8 | 30.1±1.1 | 35±1.8 | 22.6±21 | 23.2±1.4 | 24.2±1.9 | 24.8±2.1 |
- Citation: Malaguarnera M, Pistone G, Elvira R, Leotta C, Scarpello L, Liborio R. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005; 11(45): 7197-7202
- URL: https://www.wjgnet.com/1007-9327/full/v11/i45/7197.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i45.7197